recorlev
Generic: levoketoconazole
recorlev: sourced relationships with 2 companies · 1 FDA decision.
recorlev evidence translation
What we can confirm
1 FDA record
What it means
More than one company relationship is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.
What to watch
Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected
Prepared research question
What is verified about recorlev, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
endogenous Cushing's syndromeTreatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome for whom surgery is not an option or has not been curative
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| Strongbridge Biopharma plc (SBBP) endogenous Cushing's syndrome | Phase 3 |
| Xeris Biopharma Holdings, Inc. (XERS) Treatment of endogenous hypercortisolemia in adult patients … | Approved |
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with recorlev?
recorlev has dated SEC/FDA relationship records for Strongbridge Biopharma plc, Xeris Biopharma Holdings, Inc..
What is recorlev's latest FDA decision?
The most recent tracked FDA decision for recorlev is Approval, dated December 30, 2021.